ClinicalTrials.gg
CompletedNCT04225260READY-4Updated Jun 18, 2023Results posted

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

A Phase 3 interventional study of botulinum toxin neuromodulator in Glabellar Lines and Lateral Canthal Lines, sponsored by Galderma R&D. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
902
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

02

Conditions studied

  • Glabellar Lines
  • Lateral Canthal Lines
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
  • Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than the product).
  • Female who is pregnant, breast feeding, or intends to conceive a child during the study.
  • Known allergy or to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
902 participants (actual)

Study arms

  • Experimental
    QM1114-DP in the LCL and the GL areas

    The investigational product (QM1114-DP) is a BoNT Type A. At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines.

    Biological: botulinum toxin neuromodulator

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown

    4-point scale

    Time frame: Week 4

  2. Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile

    4-point scale

    Time frame: Week 4

07

Results

Posted Jun 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneQM1114-DP in the LCL and the GL Areas
Started902
Completed790
Not completed112

Outcome measures

PrimaryPercentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown

4-point scale

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown
ParticipantsQM1114-DP in the GL
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown769
PrimaryPercentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile

4-point scale

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile
ParticipantsQM1114-DP in the LCL
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile719

Adverse events

Collected over 12 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QM1114-DP in the LCL and the GL Areas1/902 (0.1%)23/902 (2.5%)243/902 (26.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventQM1114-DP in the LCL and the GL Areas
AppendicitisInfections and infestations1/902
COVID-19Infections and infestations1/902
Cholecystitis infectiveInfections and infestations1/902
Post procedural infectionInfections and infestations1/902
Urinary Tract InfectionInfections and infestations1/902
UrosepsisInfections and infestations1/902
Abdominal Pain UpperGastrointestinal disorders1/902
Gastric ulcerGastrointestinal disorders1/902
Gastrointestinal perforationGastrointestinal disorders1/902
Adnocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/902
Most frequent other events
Showing 10 of 11
Most frequent other events
EventQM1114-DP in the LCL and the GL Areas
Injection site PainGeneral disorders65/902
Injection site bruisingGeneral disorders59/902
HeadacheNervous system disorders54/902
COVID-19Infections and infestations48/902
HypertensionVascular disorders19/902
Alanine aminotransferase increasedInvestigations16/902
Upper respiratory tract infectionInfections and infestations15/902
Urinary Tract InfectionInfections and infestations15/902
Aspartate aminotransferase increasedInvestigations15/902
Gamma-glutamyltransferase increasedInvestigations10/902

Baseline characteristics

Age, Continuous
Age, Continuous(years)QM1114-DP in the LCL and the GL Areas
Mean47.2 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)QM1114-DP in the LCL and the GL Areas
Female775
Male127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QM1114-DP in the LCL and the GL Areas
American Indian or Alaska Native1
Asian12
Native Hawaiian or Other Pacific Islander5
Black or African American26
White820
More than one race16
Unknown or Not Reported22
Region of Enrollment
Region of Enrollment(participants)QM1114-DP in the LCL and the GL Areas
United States902
08

Study locations

30 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 35205, United States
  • Investigate MD, LLC.
    Scottsdale, Arizona 85255, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Rejuva Medical Aesthetics, LLC
    Los Angeles, California 90025, United States
  • Westside Aesthetics
    Los Angeles, California 90025, United States
  • Marcus Facial Plastic Surgery
    Redondo Beach, California 90277, United States
  • The Maas Clinic Research Center
    San Francisco, California 94115, United States
  • ArteMedica
    Santa Rosa, California 95401, United States
  • AboutSkin Research, LLC
    Greenwood Village, Colorado 80111, United States
  • Modern Dermatology PC
    Westport, Connecticut 06880, United States
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
  • Steven Fagien, MD, PA
    Boca Raton, Florida 33431, United States
  • Susan H. Weinkle, M.D
    Bradenton, Florida 34209, United States
  • Miami Skin and Vein LLC
    Coral Gables, Florida 33134, United States
  • Mayoral Dermatology
    Coral Gables, Florida 33143, United States
  • Skin Research Institute, LLC
    Coral Gables, Florida 33146, United States
  • Research Institute of SouthEast, LLC
    West Palm Beach, Florida 33401, United States
  • Hamilton Research LLC
    Alpharetta, Georgia 30022, United States
  • Chicago Cosmetic Surgery and Dermatology, Inc
    Chicago, Illinois 60654, United States
  • Pure Dermatology, LLC
    Metairie, Louisiana 70001, United States
  • SkinCare Physicians
    Chestnut Hill, Massachusetts 02467, United States
  • Skin Laser and Surgery Specialist of NY/NJ
    Hackensack, New Jersey 07601, United States
  • Elite Aesthetic Research
    Cincinnati, Ohio 45236, United States
  • Aventiv Research, Inc.
    Dublin, Ohio 43016, United States
  • Dallas Plastic Surgery Institute
    Dallas, Texas 75231, United States
  • Center for Advanced Clinical Research
    Dallas, Texas 75254, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • SkinDC, PLLC
    Arlington, Virginia 22209, United States
  • EthiQ2 Research, LLC
    Mequon, Wisconsin 53092, United States
  • Jose Raul Montes Eyes & Facial Rejuvenation LLC
    San Juan, 00917, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2021, 14 months.

Results were first posted in Jun 2023, 2 years 2 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 13, 2020
StartActual
Jan 27, 2020
Primary completionActual
Apr 12, 2021
CompletionActual
May 21, 2021
Results delay requested
May 26, 2021
Results first posted
Jun 18, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04225260
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jan 27, 2020
Primary completion
Apr 12, 2021
Completion
May 21, 2021
Results posted
Jun 18, 2023
Last update
Jun 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion